CA2712965A1 - Antigen-binding polypeptides against cartilage degeneration - Google Patents

Antigen-binding polypeptides against cartilage degeneration Download PDF

Info

Publication number
CA2712965A1
CA2712965A1 CA2712965A CA2712965A CA2712965A1 CA 2712965 A1 CA2712965 A1 CA 2712965A1 CA 2712965 A CA2712965 A CA 2712965A CA 2712965 A CA2712965 A CA 2712965A CA 2712965 A1 CA2712965 A1 CA 2712965A1
Authority
CA
Canada
Prior art keywords
antigen
polypeptide
cartilage
binding polypeptide
anyone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2712965A
Other languages
English (en)
French (fr)
Inventor
David Urech
Peter Lichtlen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Delenex Therapeutics AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2712965A1 publication Critical patent/CA2712965A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2712965A 2008-02-05 2009-02-05 Antigen-binding polypeptides against cartilage degeneration Abandoned CA2712965A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2631708P 2008-02-05 2008-02-05
US61/026,317 2008-02-05
US8887608P 2008-08-14 2008-08-14
US61/088,876 2008-08-14
PCT/CH2009/000045 WO2009097704A1 (en) 2008-02-05 2009-02-05 Antigen-binding polypeptides against cartilage degeneration

Publications (1)

Publication Number Publication Date
CA2712965A1 true CA2712965A1 (en) 2009-08-13

Family

ID=40568129

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2712965A Abandoned CA2712965A1 (en) 2008-02-05 2009-02-05 Antigen-binding polypeptides against cartilage degeneration

Country Status (10)

Country Link
US (1) US20110002927A1 (https=)
EP (1) EP2240515A1 (https=)
JP (1) JP2011510667A (https=)
CN (1) CN101939335B (https=)
AU (1) AU2009212079B2 (https=)
BR (1) BRPI0907485A2 (https=)
CA (1) CA2712965A1 (https=)
IL (1) IL206720A0 (https=)
RU (1) RU2010136988A (https=)
WO (1) WO2009097704A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013008697A2 (pt) 2010-09-24 2016-06-21 Massachusetts Inst Technology géis nanoestruturados capazes de liberação controlada de agentes encapsulados
CN104231086B (zh) * 2013-08-27 2019-12-13 北京韩美药品有限公司 双功能融合蛋白及其制备方法和用途
KR101860117B1 (ko) 2013-12-13 2018-05-21 유겐가이샤 머큐리 에셋 매니지먼트 관절 연골 이미징 조성물
EP3452094B1 (en) * 2016-05-06 2021-11-17 The Brigham and Women's Hospital, Inc. Binary self assembled gels for controlled delivery of encapsulated agents to cartilage
CA3113948A1 (en) 2018-10-11 2020-04-16 Alivio Therapeutics, Inc. Non-injectable hydrogel formulations for smart release
CN120865334A (zh) * 2025-03-26 2025-10-31 中山大学附属第五医院 一种靶向软骨的阳离子肽类化合物及其制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
KR101457223B1 (ko) * 2005-06-07 2014-11-04 에스바테크 - 어 노바티스 컴파니 엘엘씨 ＴＮＦα를 억제하는 안정적이고 가용성인 항체
ES2820837T3 (es) * 2006-07-10 2021-04-22 Esbatech Alcon Biomed Res Unit Anticuerpos scFv que pasan las capas epitelial y/o endotelial

Also Published As

Publication number Publication date
RU2010136988A (ru) 2012-03-20
JP2011510667A (ja) 2011-04-07
EP2240515A1 (en) 2010-10-20
WO2009097704A1 (en) 2009-08-13
CN101939335A (zh) 2011-01-05
BRPI0907485A2 (pt) 2015-08-04
US20110002927A1 (en) 2011-01-06
AU2009212079A1 (en) 2009-08-13
CN101939335B (zh) 2015-02-11
IL206720A0 (en) 2010-12-30
AU2009212079B2 (en) 2012-08-30

Similar Documents

Publication Publication Date Title
Urech et al. Anti-inflammatory and cartilage-protecting effects of an intra-articularly injected anti-TNFα single-chain Fv antibody (ESBA105) designed for local therapeutic use
KR102249078B1 (ko) 요법에 사용하기 위한 항-아드레노메둘린 (adm) 항체 또는 항-adm 항체 단편 또는 항-adm 비-ig 스캐폴드
AU2009212079B2 (en) Antigen-binding polypeptides against cartilage degeneration
US9304127B2 (en) Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment for use in therapy
Moltó et al. Anti-IL-1 molecules: new comers and new indications
JP5022216B2 (ja) 自己炎症性疾患を処置するためのｉｌ−１アンタゴニストを使用する方法
TW200412999A (en) Low dose methods for treating disorders in which TNF α activity is detrimental
NZ624873A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition
PT2390267E (pt) Anticorpos estáveis e solúveis que inibem tnf(alfa)
JP2017155050A (ja) 慢性又は急性疾患に罹患している患者の体液平衡を調整するための抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場
JP2021181487A (ja) 新規な抗ｃｄ３抗体およびその使用
JP2015502930A (ja) 慢性若しくは急性疾患又は急性病態に罹患している患者の死亡リスクを低減するための抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場
JP2023138982A (ja) インターロイキン－１７（ｉｌ－１７）アンタゴニストを使用して腱障害を治療する方法
CN101884784B (zh) 具有促细胞分裂活性的Bv8的核酸和多肽
CN100500209C (zh) Clk-肽和slk-肽
KR102741829B1 (ko) 골관절염의 치료에 사용하기 위한 실데나필
WO2002070009A1 (en) Preventives/remedies for thickened scar, keloid or chronic arthritic diseases
Coll Therapeutic targeting of inflammasome signaling by blocking interleukin-1
CN119546340A (zh) 使用白细胞介素-17（il-17）拮抗剂选择性治疗肌腱病的方法
KR20010024549A (ko) Ｔｎｆ 길항제의 패혈증 치료를 위한 약제로서의 용도
Urech et al. Anti-inflammatory and cartilage-protecting effects of an intra-articularly injected anti-TNF-α scFv (ESBA105) designed for local therapeutic use
CN117355323A (zh) 用于治疗骨关节炎的方法
EP4000627A1 (en) Treatment of abdominal aortic aneurysm after its clinical manifestation
WO2020000063A1 (en) Rheumatoid arthritis treatment
HK1088837B (en) Clk-peptide and slk-peptide

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140121

FZDE Discontinued

Effective date: 20160205